Inserm CIC1401, Bordeaux PharmacoEpi, university Bordeaux, 33076 Bordeaux, France.
Hôpital Pitié-Salpêtrière, 75013 Paris, France.
Therapie. 2019 Sep;74(4):459-468. doi: 10.1016/j.therap.2019.02.001. Epub 2019 Feb 25.
Studies of survival after myocardial infarction (MI) are often based on intention to treat analyses of controlled trials.
Describe long-term survival after MI in France.
Six-year cohort study of patients recruited within 3 months after MI. Primary outcome was all-cause death. Vital status was verified in the national death registry. Analysis used Cox models with time-dependent variables and propensity scores.
Five thousand five hundred and twenty-seven (5527) subjects were included, 62.1±13 years old, 77.6% male, 9.6% smokers, 16.7% diabetic, 13.3% with previous MI. Up to 99% of patients were initially prescribed secondary prevention drugs (aspirin and/or other antiplatelet agents, beta-blockers, statins or other lipid-lowering agents, angiotensin converting enzyme inhibitors or angiotensin receptor blockers); 73% had all four classes. Overall 6-year mortality was 13.1% [95% confidence interval 12.3 to 14.0%], 2.34 per hundred patient-years (% PY); 49% returned all or all but one of the possible questionnaires (compliant [C]), 50.8% did not (non-compliant [NC]). The main predictors for death were non-compliance with study protocol (death rates NC 2.98% PY, C 1.69%PY, hazard ratio (HR) 3.13 [2.63-3.57]); increasing age at inclusion (HR up to 15.7 [10.7-23.2] for age ≥80); diabetes (1.39 [1.17-1.65]); smoking at inclusion (1.76 [1.27-2.44]), previous MI (1.46 [1.22-1.75]). Beta-blockers (0.79 [0.64-0.96]), statins (0.68 [0.51-0.90]), and enrolment in physical rehabilitation programs (0.74 [0.62-0.89]) were associated with a lower death rate.
Association of mortality with non-compliance to study protocol probably indicates general non-compliance with prevention. Analyses of treatment effects were hindered by paucity of events and of unexposed patients.
心肌梗死(MI)后生存的研究通常基于对照试验的意向治疗分析。
描述法国 MI 后的长期生存情况。
对 MI 后 3 个月内招募的患者进行 6 年队列研究。主要结局为全因死亡。在国家死亡登记处核实生存状态。分析采用时间依赖性变量和倾向评分的 Cox 模型。
共纳入 5527 例患者(62.1±13 岁,77.6%为男性,9.6%为吸烟者,16.7%为糖尿病患者,13.3%有既往 MI)。初始处方二级预防药物(阿司匹林和/或其他抗血小板药物、β受体阻滞剂、他汀类药物或其他降脂药物、血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂)的患者高达 99%;73%的患者服用了全部 4 类药物。总体 6 年死亡率为 13.1%(95%置信区间 12.3%至 14.0%),每 100 患者年 2.34 人死亡(%PY);49%的患者返回了全部或除一份之外的所有可能的问卷(符合[C]),50.8%的患者未返回(不符合[NC])。死亡的主要预测因素是非遵守研究方案(NC 组死亡率 2.98%PY,C 组 1.69%PY,危险比(HR)3.13[2.63-3.57]);纳入时年龄增加(年龄≥80 岁的 HR 高达 15.7[10.7-23.2]);糖尿病(1.39[1.17-1.65]);纳入时吸烟(1.76[1.27-2.44]),既往 MI(1.46[1.22-1.75])。β受体阻滞剂(0.79[0.64-0.96])、他汀类药物(0.68[0.51-0.90])和参加身体康复计划(0.74[0.62-0.89])与死亡率降低相关。
死亡率与不遵守研究方案相关,可能表明一般预防措施的不遵守。由于事件和未暴露患者的缺乏,治疗效果的分析受到阻碍。